Ohio State Wexner Medical Center first in U.S. to implant device for knee osteoarthritis
Surgeons at The Ohio State University Wexner Medical Center are the first in the U.S. to implant a new device designed to relieve knee pain and help people with osteoarthritis prevent or delay knee replacements.
For the millions who suffer with the daily pain and stiffness of osteoarthritis, treatments to slow the progression of the disease are limited. A clinical trial is testing the Calypso Knee System and the
device’s ability to extend the functional life of the joint, thus allowing patients to remain active without knee pain.
“This device works like a shock absorber to take pressure off the inside of the knee while creating a cushion similar to what cartilage provides in a healthy joint,” said Dr. David Flanigan, orthopedic surgeon at The Ohio State University Wexner Medical Center who performed the surgery. “The hope is that it increases joint functionality, reduces pain and delays a total knee arthroplasty for years or even decades.”
Developed by Moximed Inc., the device is designed to treat the symptoms of osteoarthritis on the inner knee, the most commonly affected area. Without altering the anatomy or removing tissues or bone from the knee itself, the implant absorbs excess knee loads that cause pain in osteoarthritic joints.
“We hope this will be an opportunity for patients with osteoarthritis to remain active without pain for a much longer period of time,” Flanigan said.
Researchers will study approximately 80 trial participants who receive the implant. Ohio State Wexner Medical Center is one of only four sites in the trial.
If the trial is successful, Flanigan expects the device could soon be available to patients across the country.
Those interested in learning more about the clinical trial should visit: http://go.osu.edu/ChhG
More from Ohio State
Ohio State first to use new heart failure treatment that could help millions
Heart failure patients have a new treatment option after cardiologists at The Ohio State Wexner Medical Center were the first in the U.S. to use a pulmonary neuromodulation system.
What Outpatient Care New Albany means for the future of central Ohio health care
We've turned our attention to how central Ohioans can reach their best health possible — conveniently and affordably.
Novel gene therapy offers hope for rare neurological disease
New gene therapy helps children born with a rare genetic disorder called AADC deficiency that causes severe physical and developmental disabilities. Researchers at The Ohio State University Wexner Medical Center and The Ohio State University College of Medicine say this gene therapy offers hope to those living with incurable genetic and neurodegenerative diseases.
